CFL1 and hepatocellular carcinoma: For the HCC patients from TCGA, log rank analysis also demonstrated that HCC patients with high CFL1 expression had poorer overall survival, which was 45.7 and 81.9 months (P = 0.0037; Figure 1E) in patients with high and low CFL1, respectively, and the recurrence-free survival was 21.23 and 33 months (P = 0.065; Figure 1F), these results also verified our findings.